journal
MENU ▼
Read by QxMD icon Read
search

International Journal of Clinical Pharmacology and Therapeutics

journal
https://read.qxmd.com/read/30738500/safety-of-drug-combinations-based-on-psychoactive-agents-in-the-treatment-of-obesity
#1
Marcela Rodríguez-Flores, Martha Kaufer-Horwitz, Eduardo García-García
No abstract text is available yet for this article.
February 10, 2019: International Journal of Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/30738499/safety-of-drug-combinations-based-on-psychoactive-agents-in-the-treatment-of-obesity-a-reply-by-the-authors
#2
Juan Gerardo Reyes-Garcia
No abstract text is available yet for this article.
February 10, 2019: International Journal of Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/30738498/lines-of-therapy-with-biological-drugs-in-dermatology-gastroenterology-and-rheumatology-practices-in-germany
#3
Karel Kostev, Anna Bauer, Louis Jacob
OBJECTIVE: The goal of the present study was to investigate lines of therapy with biological drugs in patients followed in dermatology, gastroenterology, and rheumatology practices in Germany. MATERIALS AND METHODS: The study included patients aged 18 years or over who had received a biological therapy in dermatology, gastroenterology, or rheumatology practices in Germany in 2017 (index date). The primary outcome of the study was the prevalence of different lines of therapy (first-, second-, third-, and at least fourth-line therapies) by type of practice, age, and gender...
February 10, 2019: International Journal of Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/30738497/evaluation-of-bleeding-adverse-events-associated-with-oral-p2y12-inhibitors-use-in-the-food-and-drug-administration-adverse-event-reporting-system
#4
Ahmed I Fahmy, Mohamed A Mekkawy, Adel Abou-Ali
INTRODUCTION: P2Y12 inhibitors show different bleeding-related safety profiles in premarketing trials. However, little is known about their potential safety from spontaneous reporting systems and postmarketing data. OBJECTIVE: To describe and evaluate the bleeding-related adverse events associated with use of P2Y12 inhibitors utilizing data from the FDA Adverse Event Reporting System (FAERS) database. MATERIALS AND METHODS: We identified adverse events reports listing clopidogrel, prasugrel, or ticagrelor as the primary suspected agent in the FAERS database from the 1st quarter of 2014 to the 4th quarter of 2016...
February 10, 2019: International Journal of Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/30738496/comparison-of-n-glycans-expressed-in-tumor-tissues-with-those-expressed-in-adjacent-non-tumor-tissues-of-colorectal-cancer-patients
#5
Eunhee Ji
BACKGROUND: The associations between colorectal cancer (CRC) progression and changes in N-glycan expression suggest the potential for new biomarkers and targeted cancer therapies. This study was performed to analyze N-glycans and to compare their expression profiles in tumor and corresponding adjacent non-tumor (control) tissues in stage I and IV CRC patients to examine N-glycans as potential prognostic markers. MATERIALS AND METHODS: Six adult CRC patients, including 3 in stage I and 3 in stage IV who underwent curative surgery were enrolled in this study...
February 10, 2019: International Journal of Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/30738495/acute-tubulointerstitial-nephritis-caused-by-rifampicin-an-increasing-and-often-overlooked-side-effect-in-elderly-patients
#6
Manabu Nagata, Goh Ohji, Kentaro Iwata
BACKGROUND: There are many side effects of antituberculous drugs, however, renal failure is relatively rare. Therefore, this side effect is thought to be unrecognized by most physicians. We experienced one case of acute renal failure caused by antituberculous therapy (rifampicin). CASE REPORT: A 64-year-old Japanese male developed tuberculous pleuritis. Six weeks after starting isoniazid (INH), rifampicin (RFP), and ethambutol (EB), his renal function worsened. We temporarily stopped antituberculous therapy, but the patient's renal failure did not improve, and he was admitted to our hospital for renal biopsy...
February 10, 2019: International Journal of Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/30704556/modified-serum-creatinine-derived-equations-with-muscle-mass-adjusted-estimation-of-renal-function-and-serum-cystatin-c-derived-estimated-glomerular-filtration-rate-in-elderly-individuals
#7
Michiko Kawakami, Sumio Hirata, Masanari Mizuta, Daisuke Hidaka, Hiroka Sano, Kuniya Isobe, Sakura Nakatani, Yuki Narita
AIMS: Serum creatinine (Cr)-derived estimated renal function indices are overestimated in elderly patients with reduced muscle mass (MM). We sought to identify equations correlated with measured glomerular filtration rate (mGFR) and assess the effect of bioelectrical impedance analysis (BIA)- or arm muscle circumference (AMC)-determined MM on performance. MATERIALS AND METHODS: This study involved 20 elderly patients aged 76.0 ± 6.8 (65 - 85) years, including 5 bedridden patients...
February 1, 2019: International Journal of Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/30704555/cardiac-toxicity-of-combined-vemurafenib-and-cobimetinib-administration
#8
Roberto Fiocchi, Mauro Gori, Filippo Taddei, Laura Trevisani, Mariapina Gallo, Georgios Eleftheriou
Vemurafenib and cobimetinib are extremely effective in treating V600E-mutated metastatic melanoma, but their use is associated with toxic cardiac effects. Vemurafenib-induced prolonged QTc interval may be associated with ventricular fibrillation and sudden cardiac death. Cobimetinib-induced myocardial damage may lead to severely reduced heart function and lethal heart failure. Few data are available about the time course of recovery after these side effects. We provide the first description of cardiac recovery after potentially fatal cardiac side effects due to vemurafenib and cobimetinib administration...
February 1, 2019: International Journal of Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/30686291/a-meta-analysis-of-the-influence-of-ugt1a6-genetic-polymorphisms-on-valproic-acid-pharmacokinetics
#9
Su Cheol Kim, Myeong Gyu Kim
OBJECTIVES: Genetic polymorphisms in UGT1A6 might contribute to interindividual variability in the pharmacokinetics of valproic acid (VPA). However, whether the 541A>G and 552A>C variants decrease VPA concentration remains controversial. Herein, we performed a meta-analysis to evaluate the influence of UGT1A6 genetic polymorphisms on VPA pharmacokinetics. MATERIALS AND METHODS: Searches, two-step selection, data extraction, and quality assessment were performed using a conventional protocol, and the influence of UGT1A6 genetic polymorphisms on concentration-to-dose ratio was quantitatively assessed by pooled analysis using the Comprehensive Meta-Analysis program...
January 28, 2019: International Journal of Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/30686290/voriconazole-trough-concentration-and-hepatotoxicity-in-patients-with-low-serum-albumin
#10
Atsushi Hirata, Keisuke Noto, Ryosuke Ota, Satoshi Yokoyama, Kouichi Hosomi, Mitsutaka Takada, Hiroshi Matsuoka
OBJECTIVE: We aimed to investigate the relationship between voriconazole (VRCZ) trough concentrations and hepatotoxicity and to evaluate whether the recommended trough concentration is adequate in our clinical setting. MATERIALS AND METHODS: A retrospective study was performed to investigate the relationship between serum VRCZ concentrations and the development of hepatotoxicity at the Kindai University Nara Hospital. Patients treated with VRCZ from March 2010 to January 2018 were identified from the medical records...
January 28, 2019: International Journal of Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/30663980/population-pharmacokinetics-and-dosage-optimization-of-tacrolimus-in-pediatric-patients-with-nephrotic-syndrome
#11
Xiaoqing Wang, Ye Han, Chaoyang Chen, Lingyue Ma, Huijie Xiao, Ying Zhou, Yimin Cui, Fang Wang, Baige Su, Yong Yao, Jie Ding
OBJECTIVES: The aims of this study were to investigate the population pharmacokinetic (PPK) characteristics of tacrolimus in Chinese children with nephrotic syndrome and to apply it in clinical practice. MATERIALS AND METHODS: A total of 137 concentrations from 61 patients were collected from routine therapeutic drug monitoring data between 2011 and 2018. Population modeling was performed with the nonlinear mixed-effects model (NONMEM) program, using a one-compartment model with first-order absorption and elimination...
January 21, 2019: International Journal of Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/30663979/adherence-to-the-guidelines-for-antiulcer-drug-prescription-in-patients-receiving-low-dose-aspirin-therapy-in-japan
#12
Makiko Iwasawa, Keiko Sagami, Satoshi Yokoyama, Kouichi Hosomi, Mitsutaka Takada
OBJECTIVE: Prevalence of guideline adherence for antiulcer drug prescription in patients receiving low-dose aspirin (LDA) therapy was examined and the association of risk factors with the adherence was assessed. MATERIALS AND METHODS: A retrospective cohort study using a population-based longitudinal healthcare database was conducted. Claims data between January 2005 and April 2016 were analyzed. A total of 3,079 patients were included in the study. The selected patients taking LDA were divided into two categories: those taking and those not taking antiulcer drugs in an inpatient setting...
January 21, 2019: International Journal of Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/30663978/multiple-severe-vertebral-fractures-during-the-3-month-period-following-a-missed-dose-of-denosumab-in-a-postmenopausal-woman-with-osteoporosis-previously-treated-with-alendronate
#13
Francisco Bandeira, Gustavo Torres, Elba Bandeira, Morgana B Duarte, Ana Maíra Nóbrega, Leonardo Bandeira
Denosumab is a monoclonal antibody that decreases bone resorption and increases bone mass and strength in trabecular and cortical bone leading to a reduction in fracture in women and men. Its effects are reversed after discontinuation. Recently, there has been concern about the discontinuation of denosumab and the increased risk of multiple vertebral fractures that would be associated with rapid bone loss due to high bone turnover and consequent increase in markers of bone remodeling, far above the baseline values...
January 21, 2019: International Journal of Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/30663977/a-phase-i-randomized-double-blinded-single-dose-study-evaluating-the-pharmacokinetic-equivalence-of-the-biosimilar-ibi305-and-bevacizumab-in-healthy-male-subjects
#14
Hong Zhang, Xiaoxue Zhu, Haijing Wei, Cuiyun Li, Hong Chen, Xiaojiao Li, Min Wu, Jingrui Liu, Guiling Chen, Hui Zhou, Shirui Zheng, Yanhua Ding
OBJECTIVE: To compare the pharmacokinetic (PK) profiles, immunogenicity, and safety of the proposed biosimilar IBI305 with those of bevacizumab in healthy male subjects. DESIGN: A phase I, randomized, double-blinded, two-arm, parallel-group study. SETTINGS: The study was conducted in The First Hospital of Jilin University, Changchun, China, from March 2017 to November 2017. PARTICIPANTS: A total of 100 healthy male subjects were enrolled, with 48 in the IBI305 group and 50 in bevacizumab group included in the final analysis...
January 21, 2019: International Journal of Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/30574867/comparative-efficacy-and-safety-of-biosimilar-rituximab-and-originator-rituximab-in-combination-with-methotrexate-in-patients-with-active-rheumatoid-arthritis-a-bayesian-network-meta-analysis
#15
Sang-Cheol Bae, Young Ho Lee
OBJECTIVE: We aimed to assess the relative efficacy and safety of biosimilar rituximab and originator rituximab plus methotrexate (MTX) compared to those of placebo plus MTX in patients with active rheumatoid arthritis (RA). MATERIALS AND METHODS: We performed a Bayesian network meta-analysis to combine direct and indirect evidence from randomized controlled trials (RCTs) that examined the efficacy and safety of biosimilar+MTX and rituximab+MTX versus placebo+MTX (MTX group) in patients with active RA despite treatment with MTX and/or tumor necrosis factor (TNF) blockers...
December 21, 2018: International Journal of Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/30574866/trastuzumab-biosimilar-in-metastatic-breast-cancer-evaluating-equivalence-with-originator-using-network-meta-analysis
#16
Daniele Mengato, Marco Chiumente, Andrea Messori
OBJECTIVE: The European Medicines Agency (EMA) and the Food and Drug Administration (FDA) have recently approved four different trastuzumab biosimilars, marketed by different pharmaceutical companies. Biosimilars, unlike their originators, are typically supported by less clinical data about safety and efficacy. The objective of our analysis was to demonstrate that one of the approved trastuzumab biosimilars (MYL-1401O) is as effective as its originator in terms of hazard ratio (HR) of progression-free survival (PFS)...
December 21, 2018: International Journal of Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/30574865/genotype-based-enrichment-study-design-for-minimizing-the-sample-size-in-bioequivalence-studies-using-tolterodine-and-cyp2d6-genotype
#17
Minkyung Oh, Chang-Woo Yeo, Ho-Sook Kim, Jihong Shon, Jae-Gook Shin
OBJECTIVE: The objective of this study was to explore a pharmacogenomic information-based enrichment study design for reducing the sample size in bioequivalence (BE) studies using tolterodine and CYP2D6 genotypes. MATERIALS AND METHODS: A BE study of tolterodine was performed in a randomized, open-label, 2×2 cross-over design. A two one-sided test (TOST) was executed for pharmacokinetic (PK) parameters of tolterodine, and their geometric mean ratios (GMRs) with 90% confidence intervals (CIs) were estimated...
December 21, 2018: International Journal of Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/30574864/pharmacokinetic-comparison-of-gemigliptin-50-mg-and-metformin-500-mg-as-a-fixed-dose-combination-and-loose-combination
#18
Sang Won Lee, Sang-In Park, SeungHwan Lee, Jae-Yong Chung, Kyung-Sang Yu
BACKGROUND: Metformin and dipeptidyl peptidase-4 (DPP-IV) inhibitors are commonly combined to treat patients with diabetes mellitus (DM). A new fixed-dose combination (FDC) drug containing gemigliptin, a DPP-IV inhibitor, and sustained-release metformin has been developed. This study aimed to compare the PKs and tolerability of FDC versus loose combination of gemigliptin 50 mg and metformin 500 mg. MATERIALS AND METHODS: A randomized, open-label, two-treatment, two-period, two-sequence, crossover study was conducted in 28 healthy subjects, who received a single oral dose of an FDC tablet of gemigliptin (50 mg) and sustained-release metformin (500 mg) or were coadministered gemigliptin (50 mg) and extended-release metformin (500 mg) with a 1-week washout...
December 21, 2018: International Journal of Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/30526812/comparison-of-the-effects-of-peramivir-and-oseltamivir-on-the-rise-in-platelet-count-in-patients-with-or-without-proven-influenza
#19
Young-Gon Kim, Sun-Young Ko, Sung Woo Lee
OBJECTIVE: Neuraminidase (sialidase) inhibitors are considered to delay platelet clearance through the inhibition of platelet desialylation. A novel neuraminidase inhibitor, peramivir, was recently approved for intravenous administration by the US FDA. We aimed to compare the effects of peramivir and oseltamivir on patient platelet count. MATERIALS AND METHODS: Consecutive patients who were treated with peramivir or tested positive for influenza between January 2015 and December 2017 were analyzed...
December 11, 2018: International Journal of Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/30526811/association-between-use-of-antiemetics-antipsychotics-or-antidepressants-and-the-risk-of-parkinson-s-disease
#20
Ju-Young Shin, Ha-Lim Jeon, Han Eol Jeong, Hyeo-Il Ma, Sunmee Jang
OBJECTIVE: Antipsychotics, antidepressants, and antiemetics are well-known causative agents of parkinsonism. However, it is not certain that the use of these medications increases the risk of Parkinson's disease (PD). We aim to define the risk of PD associated with use of antipsychotic, antidepressant, or antiemetic therapy. MATERIALS AND METHODS: We conducted a population-based nested case-control study using data from the South Korean health insurance database...
December 11, 2018: International Journal of Clinical Pharmacology and Therapeutics
journal
journal
31654
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"